GENE ONLINE|News &
Opinion
Blog

2021-07-14| COVID-19

COVID-19: FDA Adds New Warning For a Rare Autoimmune Disorder to J&J’s Vaccine

by Daniel Ojeda
Share To

On July 12th, Johnson & Johnson announced that the FDA had added a new warning to its COVID-19 vaccine. This the second time the vaccine has been linked to a very rare but potentially deadly adverse event. The benefits of the vaccine outweigh the risks, but this development could contribute to vaccine hesitancy. 

The J&J vaccine was approved for emergency use in February 2021. The vaccine is 85% effective against the original COVID-19 variant, and it leads to the production of neutralizing antibodies against the Beta and Delta variants.

Additionally, J&J pledged to sell it on a not-for-profit basis. All these factors made the J&J vaccine an integral component of vaccination efforts around the world. The EU alone ordered 200 million doses, and last week it ordered an additional 40 million.

 

J&J’s Setbacks

The J&J vaccine suffered several setbacks, including manufacturing delays due to irregularities found at a Baltimore plant. The plant, owned by Emergent BioSolutions, was subcontracted to help with vaccine production. However, an inspection revealed a lack of sanitation and proper procedure. As a result, millions of doses were discarded.

Additionally, back in April, vaccination was paused due to a very rare but potentially life-threatening blood clotting. Although an extremely rare event, the CDC advised women younger than 50 years old to be aware. However, vaccination efforts resumed after it was determined that the benefits of the vaccine outweigh the risks. 

 

Guillain-Barré syndrome

After a review of the available data, the FDA added a warning for Guillain-Barre ́ syndrome (GBS), an autoimmune disease where the body’s immune system attacks the myelin fibers that coat neurons. This damage leads to weakness, tingling, problems walking, and difficulty with facial movement. In severe cases, it can lead to full-body paralysis.

The condition is extremely rare. Currently, more than 12 million people have received the J&J vaccine, and only 100 cases of GBS have been reported. That is 0.0008% of all people that received the vaccine. Of the cases, 95 required hospitalizations, and there was one reported death. Most of the cases were in men 50 older, and they occurred within 6 weeks post-inoculation. 

A higher rate of GBS has been observed with the AstraZeneca vaccine. This led European regulators to place a similar warning for that vaccine. Interestingly, the AstraZeneca and J&J vaccines use adenovirus-based vaccines. Crucially, the mRNA-based vaccines were not associated with a higher likelihood of developing GBS.

In a statement, J&J said, “We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.”

Related Article: Moderna Looks Beyond COVID as it Doses First Patient With mRNA-Based Seasonal Flu Vaccine

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends
2022-05-24
Learning From the COVID-19 Pandemic With Moderna CEO, Stéphane Bancel
2022-05-23
LATEST
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
2022-05-27
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
2022-05-27
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
2022-05-26
Stanford Touts Remote-Controllable CAR-T Cell Therapy
2022-05-26
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
2022-05-26
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!